Clinical Trial Update: Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tebentafusp and roginolisib in metastatic uveal melanoma is currently recruiting to study effects on T-cell homeostasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Roginolisib (roginolisib)
• Tebentafusp (tebentafusp)

Snippet

Sponsor: St Vincent's Hospital, Sydney | Conditions: Uveal Melanoma, Metastatic | Phase 1 | Status: RECRUITING